[IGSF11: A Novel Target for Cancer Immunotherapy]

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint blockade therapy offers significant cancer treatment benefits but faces challenges like low response rates and adverse events.
• Immunoglobulin superfamily member 11 (IGSF11) acts as an inhibitory immune checkpoint and a specific ligand for V-domain immunoglobulin suppressor of T cell activation (VISTA).

Purpose of the Study:

• To systematically review the structural characteristics, regulatory mechanisms, and VISTA interaction of IGSF11.
• To elucidate the functional role of the IGSF11/VISTA axis in the tumor microenvironment and its potential as a cancer immunotherapy target.

Main Methods:

• Literature review and systematic summary of existing research on IGSF11.
• Analysis of IGSF11 expression patterns, regulatory mechanisms, and functional consequences in various malignancies.
• Examination of studies investigating the blockade of the IGSF11-VISTA interaction.

Main Results:

• IGSF11 suppresses T cell function via the IGSF11/VISTA axis, presenting a novel target for cancer immunotherapy.
• IGSF11 is broadly expressed across tumor types, with varied regulatory mechanisms and prognostic significance depending on the cancer.
• Inhibition of IGSF11 or its interaction with VISTA demonstrates antitumor effects.

Conclusions:

• The IGSF11/VISTA axis is a critical regulator of the immune response in cancer and a promising target for novel immunotherapies.
• Understanding IGSF11's multifaceted role and regulation is essential for developing effective cancer treatments that overcome current immunotherapy limitations.